Production (Stage)
BioMarin Pharmaceutical Inc.
BMRN
$57.55
-$0.46-0.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 185.69M | 124.94M | 106.08M | 107.17M | 88.66M |
| Total Depreciation and Amortization | 22.07M | 23.61M | 19.01M | 26.46M | 27.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.10M | 120.23M | 57.33M | 52.05M | 36.35M |
| Change in Net Operating Assets | -90.46M | -83.15M | 39.06M | -66.92M | -105.39M |
| Cash from Operations | 174.39M | 185.63M | 221.48M | 118.76M | 46.97M |
| Capital Expenditure | -16.77M | -19.53M | -18.46M | -21.33M | -26.10M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.47M | 95.93M | 2.31M | 111.81M | 11.87M |
| Cash from Investing | -28.24M | 76.40M | -16.16M | 90.48M | -14.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -494.93M | -18.00K | -- |
| Issuance of Common Stock | -- | 7.86M | 4.80M | 29.42M | 7.20M |
| Repurchase of Common Stock | -38.78M | -4.91M | -5.91M | -16.79M | -49.95M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -94.00K | -3.08M | -- | -42.00K |
| Cash from Financing | -38.78M | 2.86M | -499.13M | 12.61M | -42.79M |
| Foreign Exchange rate Adjustments | -1.42M | 2.50M | -2.90M | 3.30M | 1.93M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.96M | 267.39M | -296.70M | 225.15M | -8.13M |